<DOC>
	<DOCNO>NCT02629562</DOCNO>
	<brief_summary>Multi-centre , double-blind , randomise , 2-way cross-over study investigate PK PD B12019 compare Neulasta® administer single subcutaneous ( s.c. ) dose healthy male subject . B12019 Neulasta administer s.c. injection .</brief_summary>
	<brief_title>Pharmacokinetic Pharmacodynamics B12019 Neulasta® Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male subject Age ≥18 ≤45 year BMI 22.0 28.0 kg/m2 Nonsmokers least 6 month prior study start General good health , base comprehensive medical history physical examination Adequate organ function normal laboratory value ( unless investigator considers abnormality clinically relevant ) Negative hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody human immunodeficiency virus ( HIV ) test screen Signed informed consent Known hypersensitivity Escherichia coli derived protein , pegfilgrastim , filgrastim component B12019 Neulasta® Previous exposure filgrastim pegfilgrastim History drug alcohol abuse Blood donation past 3 month prior study start , bone marrow stem cell donor past 12 month ( first dose ) Medical history haematological disease , include sickle cell disorder Recent infection ( within 1 week prior first dose ) Relevant history renal , hepatic , gastrointestinal , cardiovascular , respiratory , skin , haematological , endocrine , inflammatory neurological disease , opinion investigator may interfere aim study Participation interventional Phase I study last 3 month current followup visit schedule study , participation three study experimental drug product past 12 month prior screen Subjects ANC value outside normal laboratory range screen Use prescription overthecounter drug include vitamin within 4 week first dose Abnormalities ECG Signs dermatitis skin abnormality affect administration area surroundings History cancer</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>